Why the Incannex (ASX:IHL) share price is soaring 13%

The Incannex share price is soaring today as the company mulls a US listing. We take a closer look at its release.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price is soaring today as the company announced that it is mulling a US listing. Shares in the small-cap health care stock are currently trading 12.82% higher as a result. This has held Incannex shares to rise to a price of 22 cents.

blocks trending up

Image source: Getty Images

Why is the Incannex share price flying?

Today the Incannex share price is trading strongly higher. This comes as the company announced that it is intending to list on the US market. The company has executed a binding consulting agreement with EAS Advisors to facilitate the listing.

Incannex noted that the predominant purpose of the arrangement was for EAS to introduce it to US banks and institutions. With the aim of dual listing the company on either the Nasdaq Composite (INDEXNASDAQ: .IXIC) or the NYSE Composite (INDEXNYSEGIS: NYA). While also retaining its listing on the ASX.

It is worth noting that the term of the agreement is 12 months. EAS will be paid both with Incannex options and a standard retainer. The advisory firm is also going to assist with financial modelling, presentation preparation, and external data room maintenance. This will be on top of generating global investor awareness.

Management Comments

CEO and Managing Director of Incannex Healthcare, Joel Latham, welcomed the news by saying:

After several months of getting to know one another, Eddie and EAS have joined our broader team to evaluate opportunities to list IHL securities in the United States on one of the main markets. We have made this decision because of deep investor interest and corporate activity in both cannabinoid-based pharmaceuticals and psychedelic therapeutic endeavours in North America. We're delighted to be working with the team at EAS, which has an excellent track record of growing international awareness for ASX companies.

About the Incannex share price

The Incannex share price has performed well as of late as it recently released positive drug results.

In the last month alone, its shares are up a whopping 37.5%, easily outpacing the All Ordinaries Index (ASX: XAO). Incannex is currently valued at $229.24 million.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »